Back to News
Apr 30, 2026 12:10 PM

Eli Lilly Raises 2026 Outlook On Strong Mounjaro And Zepbound Demand

Eli Lilly and Co. (NYSE:LLY) stock is trading higher after the weight loss drug giant released better-than-expected first quarter 2026 earnings and raised fiscal 2026 guidance.

Earnings Overview Shows Strong Growth

Eli Lilly reported first-quarter adjusted earnings of $8.55 per share, beating the consensus of $6.66.

The company’s sales reached $19.79 billion, beating the consensus of $17.62 billion.

Sales jumped 56% year over year, driven by a 65% increase in volume, partially offset by a 13% decrease due to lower realized prices.

Key Products revenue grew to $13.4 billion in the quarter, led by Mounjaro and Zepbound.

Key Products revenue in the Immunology, Oncology, and Neuroscience therapeutic areas grew 160%.

Read Also:

Eli Lilly, Profluent Target Complex Genetic Diseases With AI-Driven Custom DNA Tools

Weight Loss Drugs Drive Performance

Mounjaro’s revenue increased 125% to $8.7 billion. U.S. revenue was $4.2 billion, an increase of 59%, ...